. 2021 Apr;2(4):e135-e136.

doi: 10.1016/S2666-5247(21)00039-2. Epub 2021 Feb 24.

COVID-19 drug practices risk antimicrobial resistance evolution

Ebrahim Afshinnekoo^{1

2}, Chandrima Bhattacharya^{1

2}, Ana Burguete-García³, Eduardo Castro-Nallar⁴, Youping Deng⁵, Christelle Desnues⁶, Emmanuel Dias-Neto⁷, Eran Elhaik⁸, Gregorio Iraola⁹, Soojin Jang¹⁰, Paweł P Łabaj¹¹, Christopher E Mason^{1

2

12}, Niranjan Nagarajan¹³, Michael Poulsen¹⁴, Bharath Prithiviraj¹⁵, Rania Siam^{16

17}, Tieliu Shi¹⁸, Haruo Suzuki¹⁹, Johannes Werner²⁰, Maria Mercedes Zambrano²¹, Malay Bhattacharyya²²; MetaSUB Consortium

Affiliations

¹ Department of Physiology and Biophysics, Weill Cornell Medicine, New York, USA.
² The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, USA.
³ Center for Research on Infectious Diseases, National Institute of Public Health, Cuernavaca, Mexico.
⁴ Center for Bioinformatics and Integrative Biology, Universidad Andres Bello, Santiago, Chile.
⁵ Department of Quantitative Health Sciences, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA.
⁶ Aix-Marseille University, University of Toulon, National Center for Scientific Research, French National Research Institute for Sustainable Development, Mediterranean Institute of Oceanography, Marseille, France.
⁷ Medical Genomics Group, A C Camargo Cancer Center and LIM-27, Institute of Psychiatry, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
⁸ Department of Biology, Lund University, Lund, Sweden.
⁹ Microbial Genomics Laboratory, Institut Pasteur Montevideo, Montevideo, Uruguay.
¹⁰ Discovery of Biology, Antibacterial Resistance Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
¹¹ Małopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
¹² WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, USA.
¹³ Genome Institute of Singapore, ASTAR and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
¹⁴ Section for Ecology and Evolution, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
¹⁵ Department of Biology, Brooklyn College of the City University of New York, New York, USA.
¹⁶ University of Medicine and Health Sciences, Basettere, St Kitts and Nevis.
¹⁷ Biology Department, The American University in Cairo, Cairo, Egypt.
¹⁸ The Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
¹⁹ Faculty of Environment and Information Studies, Keio University, Kanagawa, Japan.
²⁰ High Performance and Cloud Computing Group, Zentrum für Datenverarbeitung, Eberhard Karls University of Tübingen, Tübingen, Germany.
²¹ Molecular Genetics, Corporación Corpogen and Universidad Central, Bogotá, Colombia.
²² Centre for Artificial Intelligence and Machine Learning, Machine Intelligence Unit, Indian Statistical Institute, Kolkata 700108, India.

PMID: 33655229
PMCID: PMC7906697
DOI: 10.1016/S2666-5247(21)00039-2

COVID-19 drug practices risk antimicrobial resistance evolution

Ebrahim Afshinnekoo et al. Lancet Microbe. 2021 Apr.

. 2021 Apr;2(4):e135-e136.

doi: 10.1016/S2666-5247(21)00039-2. Epub 2021 Feb 24.

Authors

Affiliations

¹ Department of Physiology and Biophysics, Weill Cornell Medicine, New York, USA.
² The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, USA.
³ Center for Research on Infectious Diseases, National Institute of Public Health, Cuernavaca, Mexico.
⁴ Center for Bioinformatics and Integrative Biology, Universidad Andres Bello, Santiago, Chile.
⁵ Department of Quantitative Health Sciences, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA.
⁶ Aix-Marseille University, University of Toulon, National Center for Scientific Research, French National Research Institute for Sustainable Development, Mediterranean Institute of Oceanography, Marseille, France.
⁷ Medical Genomics Group, A C Camargo Cancer Center and LIM-27, Institute of Psychiatry, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
⁸ Department of Biology, Lund University, Lund, Sweden.
⁹ Microbial Genomics Laboratory, Institut Pasteur Montevideo, Montevideo, Uruguay.
¹⁰ Discovery of Biology, Antibacterial Resistance Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
¹¹ Małopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
¹² WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, USA.
¹³ Genome Institute of Singapore, ASTAR and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
¹⁴ Section for Ecology and Evolution, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
¹⁵ Department of Biology, Brooklyn College of the City University of New York, New York, USA.
¹⁶ University of Medicine and Health Sciences, Basettere, St Kitts and Nevis.
¹⁷ Biology Department, The American University in Cairo, Cairo, Egypt.
¹⁸ The Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
¹⁹ Faculty of Environment and Information Studies, Keio University, Kanagawa, Japan.
²⁰ High Performance and Cloud Computing Group, Zentrum für Datenverarbeitung, Eberhard Karls University of Tübingen, Tübingen, Germany.
²¹ Molecular Genetics, Corporación Corpogen and Universidad Central, Bogotá, Colombia.
²² Centre for Artificial Intelligence and Machine Learning, Machine Intelligence Unit, Indian Statistical Institute, Kolkata 700108, India.

PMID: 33655229
PMCID: PMC7906697
DOI: 10.1016/S2666-5247(21)00039-2

No abstract available

PubMed Disclaimer

Figures

**Figure**
Use of multiple COVID-19 drugs in practice Timeline of first appearance of major antiparasite, antiviral, antibacterial, and anti-inflammatory drugs for the treatment of COVID-19 in preprints, in a peer-reviewed article, as a Google search trend, as a worldwide Twitter trend, and the first time mentioned by WHO in situation reports. The other essential drugs for supportive care were first mentioned by WHO on April 14, 2020, as a part of the COVID-19 Essential Supplies Forecasting Tool.

See this image and copyright information in PMC

Cited by

Recent Advances in the Development of Antibiotics-Coated Gold Nanoparticles to Combat Antimicrobial Resistance.
Sarma PP, Rai A, Baruah PK. Sarma PP, et al. Antibiotics (Basel). 2024 Jan 26;13(2):124. doi: 10.3390/antibiotics13020124. Antibiotics (Basel). 2024. PMID: 38391510 Free PMC article. Review.
Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.
Bienvenu AL, Bestion A, Pradat P, Richard JC, Argaud L, Guichon C, Roux S, Piriou V, Paillet C, Leboucher G; Antifungal study group. Bienvenu AL, et al. Crit Care. 2022 Dec 13;26(1):384. doi: 10.1186/s13054-022-04270-z. Crit Care. 2022. PMID: 36514110 Free PMC article.
Rhodococcus strains as a good biotool for neutralizing pharmaceutical pollutants and obtaining therapeutically valuable products: Through the past into the future.
Ivshina I, Bazhutin G, Tyumina E. Ivshina I, et al. Front Microbiol. 2022 Sep 29;13:967127. doi: 10.3389/fmicb.2022.967127. eCollection 2022. Front Microbiol. 2022. PMID: 36246215 Free PMC article. Review.
An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.
Paula HSC, Santiago SB, Araújo LA, Pedroso CF, Marinho TA, Gonçalves IAJ, Santos TAP, Pinheiro RS, Oliveira GA, Batista KA. Paula HSC, et al. Braz J Med Biol Res. 2021 Dec 10;55:e11631. doi: 10.1590/1414-431X2021e11631. eCollection 2021. Braz J Med Biol Res. 2021. PMID: 34909910 Free PMC article. Review.
A global metagenomic map of urban microbiomes and antimicrobial resistance.
Danko D, Bezdan D, Afshin EE, Ahsanuddin S, Bhattacharya C, Butler DJ, Chng KR, Donnellan D, Hecht J, Jackson K, Kuchin K, Karasikov M, Lyons A, Mak L, Meleshko D, Mustafa H, Mutai B, Neches RY, Ng A, Nikolayeva O, Nikolayeva T, Png E, Ryon KA, Sanchez JL, Shaaban H, Sierra MA, Thomas D, Young B, Abudayyeh OO, Alicea J, Bhattacharyya M, Blekhman R, Castro-Nallar E, Cañas AM, Chatziefthimiou AD, Crawford RW, De Filippis F, Deng Y, Desnues C, Dias-Neto E, Dybwad M, Elhaik E, Ercolini D, Frolova A, Gankin D, Gootenberg JS, Graf AB, Green DC, Hajirasouliha I, Hastings JJA, Hernandez M, Iraola G, Jang S, Kahles A, Kelly FJ, Knights K, Kyrpides NC, Łabaj PP, Lee PKH, Leung MHY, Ljungdahl PO, Mason-Buck G, McGrath K, Meydan C, Mongodin EF, Moraes MO, Nagarajan N, Nieto-Caballero M, Noushmehr H, Oliveira M, Ossowski S, Osuolale OO, Özcan O, Paez-Espino D, Rascovan N, Richard H, Rätsch G, Schriml LM, Semmler T, Sezerman OU, Shi L, Shi T, Siam R, Song LH, Suzuki H, Court DS, Tighe SW, Tong X, Udekwu KI, Ugalde JA, Valentine B, Vassilev DI, Vayndorf EM, Velavan TP, Wu J, Zambrano MM, Zhu J, Zhu S, Mason CE; International MetaSUB Consortium. Danko D, et al. Cell. 2021 Jun 24;184(13):3376-3393.e17. doi: 10.1016/j.cell.2021.05.002. Epub 2021 May 26. Cell. 2021. PMID: 34043940 Free PMC article.

See all "Cited by" articles

References

1. Chng KR, Li C, Bertrand D. Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment. Nature Med. 2020;26:1–11. - PMC - PubMed
1. Cox MJ, Loman N, Bogaert D, O'grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020;1:e11. - PMC - PubMed
1. Sterenczak KA, Barrantes I, Stahnke T, Stachs O, Fuellen G, Undre N. Co-infections: testing macrolides for added benefit in patients with COVID-19. Lancet Microbe. 2020;1:e313. - PMC - PubMed
1. WHO Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
1. Korber B, Fischer WM, Gnanakaran S. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 drug practices risk antimicrobial resistance evolution

Affiliations

COVID-19 drug practices risk antimicrobial resistance evolution

Authors

Affiliations

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources